Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease

Current pharmacotherapy has limited efficacy and/or intolerable side effects in late-stage Parkinson’s disease (LsPD) patients whose daily life depends primarily on caregivers and palliative care. Clinical metrics inadequately gauge efficacy in LsPD patients. We explored if a D(1/5) dopamine agonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Mechelle M., Van Scoy, Lauren J., De Jesus, Sol, Hakun, Jonathan G., Eslinger, Paul J., Fernandez-Mendoza, Julio, Kong, Lan, Yang, Yang, Snyder, Bethany L., Loktionova, Natalia, Duvvuri, Sridhar, Gray, David L., Huang, Xuemei, Mailman, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216182/
https://www.ncbi.nlm.nih.gov/pubmed/37238699
http://dx.doi.org/10.3390/biom13050829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216182/
https://www.ncbi.nlm.nih.gov/pubmed/37238699
http://dx.doi.org/10.3390/biom13050829

Ejemplares similares